1 Rising prevalence of *Plasmodium falciparum* artemisinin resistance mutations in

2 Ethiopia

Bokretsion G. Brhane^{1,2*}, Abebe A. Fola^{3,4*}, Helen Nigussie², Alec Leonetti³, Moges
Kassa¹, Henok Hailgiorgis¹, Yonas Wuletaw¹, Adugna Abera¹, Hussein Mohammed¹,
Heven Sime¹, Abeba G/Tsadik¹, Gudissa Assefa⁹, Hiwot Solomon⁹, Geremew Tasew¹,
Getachew Tollera¹, Mesay Hailu¹, Jonathan J. Juliano^{5,6,7,8}, Ashenafi Assefa^{1,4},
Jonathan B. Parr^{5,6,7#} and Jeffrey A. Bailey^{3,4#}

- 8
- 9 1 Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- 10 2 Department of Microbial, Cellular, and Molecular Biology, Addis Ababa University,
- 11 Addis Ababa, Ethiopia
- 3 Department of Pathology and Laboratory Medicine, Brown University, Providence, RI,
 USA
- 14 4 Center for Computational Molecular Biology, Brown University, Providence, RI, USA
- 15 5 Institute for Global Health and Infectious Diseases and Division of Infectious
- 16 Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel
- 17 Hill, NC, USA
- 18 6 Division of Infectious Diseases, School of Medicine, University of North Carolina at
- 19 Chapel Hill, Chapel Hill, NC, USA
- 20 7 Curriculum in Genetics and Molecular Biology, School of Medicine, University of North
- 21 Carolina at Chapel Hill, Chapel Hill, NC, USA
- 22 8 Department of Epidemiology, Gilling School of Global Public Health, University of
- 23 North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 24 9 Ministry of Health, Addis Ababa, Ethiopia
- 25
- 26
- 27
- 28
- 29

It is made available under a CC-BY-NC-ND 4.0 International license .

30 Abstract

31 Ethiopia is striving to eliminate local malaria transmission by 2030, despite a recent 32 resurgence of malaria cases due to multiple factors. A significant contributor to this resurgence could be drug resistance, particularly the emergence of partial resistance to 33 34 artemisinin (ArtR) in Ethiopia and other regions of Eastern Africa. This situation highlights the necessity for genomic surveillance to monitor relevant drug resistance 35 36 markers. This study reports sentinel site-based genomic surveillance results for P. falciparum antimalarial drug resistance mutations. From 2019 to 2022, dried blood spots 37 38 (DBS) were collected from febrile outpatients ≥ 1 year of age with microscopically confirmed falciparum malaria at 12 sentinel sites across 5 regions. Molecular inversion 39 40 probe (MIP) sequencing targeted mutations associated with artemisinin and partner drug resistance, including k13, mdr1, crt, dhfr, and dhps genes, along with genome-41 wide markers to assess the complexity of infection (COI) and parasite relatedness. A 42 43 total of 1,199 falciparum-positive patients were assessed, with a median age of 20 years (IQR: 14-30) and including 463 (38.6%) females. The WHO-validated K13 R622I 44 mutation had a high but regionally variable prevalence (15.7%, range 0-58.8%). The 45 46 validated K13 A675V mutation was detected for the first time in Ethiopia in the Gambella Region (4.5%), as well as P441L and P574L mutations were detected at low 47 48 frequencies in Southern and Oromia Regions, respectively. Several partner drug 49 resistance markers were identified, with mutations in MDR1(184F), DHPS, DHFR, and CRT nearly fixed across the country. Most samples (87.2%) were monogenic infections 50 (COI=1) and showed high genetic relatedness, particularly within the health facilities. 51 52 Principal component analysis revealed regional clustering of parasites, particularly in 53 Gambella. The prevalence of K13 R622I across the country and the presence of multiple additional ArtR markers emphasizes the urgent need for rigorous monitoring of 54 artemisinin combination therapy (ACT) efficacy to detect partner drug resistance and 55 ACT failure early and its impact on malaria resurgence in Ethiopia. 56 57

- 58
- 59
- 60 Keywords
- 61 Malaria, *Plasmodium falciparum*, drug resistance, genomics, sentinel site, Ethiopia
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71

It is made available under a CC-BY-NC-ND 4.0 International license .

72 Background

Malaria remains a significant public health challenge in Africa, accounting for 73 74 approximately 95% of malaria cases and 96% of malaria deaths, predominantly affecting children under five and pregnant women¹. Despite notable progress through 75 the use of artemisinin-based combination therapies (ACTs), vector control measures, 76 and vaccines like RTS,S, the path to eliminating malaria faces formidable obstacles ^{2,3}. 77 These challenges include the emergence of drug- and diagnostic-resistant parasites^{4–7}, 78 insecticide-resistant mosquitoes⁸, new invasive mosquito species⁹, inadequate 79 healthcare infrastructure, and funding gaps¹⁰. Resistance to artemisinin poses a 80 particular threat to the efficacy of ACTs in Africa^{11,12} and progress towards malaria 81 elimination, highlighting the need for new strategies to define and mitigate the impact of 82 83 antimalarial resistance.

84

Artemisinin partial resistance (ArtR) was first reported in western Cambodia in 85 Southeast Asia in 2006-2007^{13,14} and has since spread or emerged independently in 86 other countries in the Greater Mekong Subregion¹⁵, South America¹⁶, and recently in 87 Eastern Africa¹⁷⁻¹⁹ and the Horn of Africa^{5,20}. The rise of ArtR WHO-validated markers 88 have been confirmed in Ethiopia⁵, Eritrea²⁰, Rwanda¹⁷, Uganda²¹, Tanzania⁶, and 89 Democratic Republic of the Congo (DRC)²². ArtR likely accelerates the emergence of 90 resistance to partner drugs²³, and once combined with partner drug resistance lead to 91 significant clinical failure in Southeast Asia. Frank partner drug resistance mutations 92 have not been found in Africa. Amino acid polymorphisms in the multidrug resistance 93 94 protein 1 (MDR1) and chloroquine resistance transporter (CRT) are well established 95 and partially effect susceptibility diametrically to both amodiaguine and possibly lumefantrine²⁴, which are the most common partner drugs used in ACTs in Ethiopia and 96 most of Africa. This decreased susceptibility likely further undermines ACTs increasing 97 the potential for emergence of other mutations^{4,6}. 98

99

100 Despite Ethiopia's gains in malaria control over the past two decades, the country faces increasing malaria cases in various regions, in the setting multiple challenges: First, the 101 K13 622I mutation, a validated marker of partial artemisinin resistance, has been found 102 at significant frequencies, particularly in the north of the country⁵. Second, the rise of P. 103 104 falciparum strains with hrp2 and hrp3 gene deletions complicates the reliability of rapid diagnostic tests (RDTs), contributing to diagnostic failures and potentially increasing 105 transmission^{5,7}. Third, invasive urban-adapted mosquito species^{9,25}, and increasing 106 insecticide resistance threaten malaria control efforts²⁶. Fourth, environmental and man-107 made factors such as climate change²⁷, conflict, and population movement may have 108 109 facilitated the spread of malaria, contributing to the recent resurgence. Gaps in 110 surveillance systems hinder effective tracking of disease patterns and resistance trends 111 and understanding the role of these challenges in malaria resurgence. Dissecting and

It is made available under a CC-BY-NC-ND 4.0 International license .

addressing these challenges requires enhanced surveillance, robust diagnostic tools, and innovative strategies to track and mitigate the spread of drug-resistant strains to achieve elimination goals²⁸. Genomic surveillance of molecular markers of resistance and understanding the genomic diversity of the parasite will be critical²⁹. Such surveillance helps identify resistance hotspots and informs targeted interventions such as deployment of sequential or triple ACT regimens, contributing to more effective malaria control and elimination strategies^{30,31}.

119

120 Integrating genomic data with routine surveillance systems for timely tracking of emerging and spreading resistance is crucial^{32,33}. To this end, the Ethiopian Public 121 122 Health Institute (EPHI), in collaboration with the national malaria control and elimination program, established a network of sentinel sites representative of the diverse malaria 123 124 transmission ecologies across the country. These sites collect and analyze data on 125 malaria transmission dynamics, treatment efficacy, and resistance patterns, providing 126 opportunities for evidence-based decision-making in near real-time. These sentinel sites are integral to Ethiopia's broader malaria control and elimination strategy, which aims to 127 128 reduce the disease's burden through early detection, targeted treatment, and prevention 129 efforts. This study reports an in-depth analysis of the emergence and spread of drug resistance mutations and parasite relatedness using molecular inversion probe (MIP) 130 sequencing of samples collected from 12 sentinel sites across the country. 131

132

133 Results

134 Study population

135 After filtering, 855 of 1,199 samples were included in the analysis sample set (Figure S1). Samples came from participants enrolled at all 12 sentinel site health facilities 136 (Figure 1A) across five regions (Amhara = 270, Gambella = 131, Oromia = 193, SNNP 137 = 221, Somali = 40) (Figure 1B). The median parasite density of sequenced samples 138 was 2,000 parasites/µL (range 48 to 61,000 parasites/µL) by microscopy, with better 139 sequencing coverage in samples with higher parasitemia (Figure S1). Most samples (n 140 141 = 767) were collected in 2022 and 79.2% (n = 607) were successfully genotyped, 393 collected in 2019 and 56.9% (n=224) successfully genotyped followed 39 collected in 142 143 2023 and 61.5% (n = 24) successfully genotyped. Details of samples successfully sequenced per each MIP panel summarized in Table S1 and Table S2. 144

- 145
- 146
- 147

It is made available under a CC-BY-NC-ND 4.0 International license .



148

Figure 1. Study sites and sequenced samples. A) Study sites and B) distribution of 149 samples sequenced per health facility and region. Colors indicate individual health

- 150
- facilities. 151

Prevalence and distribution of ArtR mutations 152

153 We first assessed the prevalence of WHO-validated and candidate K13 ArtR mutations 154 revealing four WHO validated K13 mutations (Figure 2A). K13 R622I was the most prevalent (15.7% [95% CI 13.2-18.2%]). Its geospatial distribution was heterogeneous 155 156 (prevalence range: 0 to 58.8%) at health facility level (Figure S2), with highest regional 157 prevalence in the north (46.9% [95% CI 40.7-53.2%] in the Amhara region) where it was first reported at 2.4% in one facility in 2014³⁴. K13 R622I was also prevalent in Erer 158 (12.9%), a Somali region Eastern part of the country, and additionally observed in low 159 frequency from health facilities from Gambela and Oromia regions but not reported from 160 health facilities from SNNP (Southern Nations, Nationalities and Peoples) region. 161

162

163 Of concern, we found three additional WHO-validated K13 mutations not previously observed in the Horn of Africa or Ethiopia in the southern half of the country where 622I 164 165 is not as prevalent. We found 6 samples with A675V (Gambella Region), 4 samples with 166 P441L (3 from Southern Region including 2 from Dilla and 1 from Secha health centers, 167 and 1 from Oromia Region in the Metehara health center) and 5 samples with P574L (Oromia Region in the Batu health center) (Table S3). We also identified an additional 168 169 14 non-synonymous mutations within and outside the K13 propeller domain with 170 variable frequencies (Figure S3). Other K13 mutations not associated with ArtR were 171 found, including K189T at 32% (CI, 27.1-38.3) prevalence across sites.

It is made available under a CC-BY-NC-ND 4.0 International license .

172 Genetic relatedness of k13 mutant parasites

To further elucidate the spatial spread of mutant parasites, we conducted IBD 173 relatedness analysis and found that there was a higher average IBD sharing estimate 174 for K13 R622I mutant isolates compared to K13 wild-type isolates (Figure 2B). This 175 176 was also true for parasites carrying P574L mutations (Figure S4B), however, parasites carrying A675V or P441L did not show significant relatedness and were in fact less 177 related compared to wildtype (Figure S4A, C). We then conducted relatedness network 178 179 analysis, using an IBD cut of ≥0.99 to detect evidence of clonal transmission, finding clustering mutant parasites clustered into pairs and networks (Figure 2C) separate from 180 181 wildtype.

182



183

Figure 2. WHO-validated K13 mutation prevalences and relatedness of 6221 184 **mutant vs wildtype parasites.** A) Spatial distribution of WHO-validated K13 mutations 185 by health facility (pie charts). Colors indicate which mutation, and pie chart size is 186 proportional to sample size per study site. B) Pairwise IBD sharing within kelch13 R6221 187 mutant versus wild parasites, showing *** significant differences ($P \square < \square 0.001$, two-188 tailed, Mann–Whitney U-test). Boxes indicate the interguartile range, the line indicates 189 the median, the whiskers show the 95% confidence intervals and dots show outlier 190 191 values. P value determined using Mann–Whitney test is shown. C) Network analysis showing highly related parasite pairs (IBD ≥ 0.99). Each node identifies a unique isolate, 192 and an edge is drawn between two isolates if they meet the IBD threshold. Isolates that 193 do not have a IBD pairwise connection above threshold are not shown. Color codes 194 correspond to K13 R622I mutant (pink) and wild parasites (blue green). 195

It is made available under a CC-BY-NC-ND 4.0 International license .

- 196
- 197
- 198

199 Prevalence of mutations associated resistance to partner drugs

200 Mutations in the *P. falciparum* multidrug-resistance gene 1 (MDR1), particularly isolates 201 that carry the N86 (wild), 184F (mutant), and D1246 (wild) haplotype have been associated with modest decreased susceptibility to lumefantrine (the first line partner 202 drug in Ethiopia, co-formulated as artemether-lumefantrine). Our analysis revealed that 203 204 99.1% ([95% CI 98.4-99.6%]) sequenced samples carried N86 (wild), followed by 98.1% ([95% CI 97.2-98.9%]) samples of D1246 (wild), and 94.8% ([95% CI 93.4-96.3%]) 205 206 carrying 184F (mutant) (Figure 3A). The overall high prevalence resulted in less spatial variation at district or health center level (data not shown). Nearly all parasites with the 207 208 ArtR K13 R622I (Figure 3A) and A567V (Figure 3B) mutations also carry the MDR1 209 NFD haplotype associated with lumefantrine resistance. The co-occurrence of ArtR and partner drug resistance mutations raises concern about the effectiveness of ACTs in 210 211 Ethiopia.



Figure 3. Co-occurrence of ArtR and lumefantrine-resistance markers in Ethiopia. Number of parasites with A) K13 622I and MDR1 N86 (wild), 184F (mutant) and D1246 (wild) and with B) K13 675V and MDR1 N86 (wild), 184F (mutant) and D1246 (wild). Only samples with calls across all loci are shown. For polygenomic infections, the

- 217 dominant haplotype (\geq 51% allele frequency) is shown.
- 218

212

We also observed a high prevalence of mutations associated with resistance to sulfadoxine-pyrimethamine (SP) and chloroquine. SP was discontinued in 2004 and is not used for intermittent preventive treatment for pregnant women (IPTp) as in other African countries. Nonetheless, SP resistance mutations persist at high prevalence. In DHFR, 98.9% ([95% CI 98.6-99.4%]) parasites had the S108N mutation, 98.5% ([95%

224 CI 97.8-99.3%]) N51I, and 65% ([95% CI 61.9-68.1%]) C59R (Figure S5A) mutations 225 associated with pyrimethamine resistance. Overall, 469 (61.6%) samples carry all three mutations (DHFR IRN, triple mutant) with low spatial heterogeneity at regional level 226 227 across the country. None of the genotyped samples carried DHFR 164L, a mutation 228 associated with higher levels of SP resistance. Analysis of markers associated with 229 sulfadoxine resistance revealed that all 907 (100%) isolates carried DHPS A437G and 83.1% ([95% CI 80.6-85.4%]) K540E, with 711 (78.8%) carrying both of these mutations 230 (DHPS GE, double mutant) (Figure S5A). The DHPS A581G mutation, shown to 231 increase SP resistance, when co-occurring with the above mutations occurred at low 232 233 frequency, 3.4% ([95% CI 2.6-5.4%]) (Figure S5A).

234

Chloroquine is widely used in Ethiopia for treatment of *Plasmodium vivax* infection. Mutations in the *P. falciparum* chloroquine (CQ) resistance transporter (CRT) were common; 896 (82.4%) parasites had the chloroquine-resistance marker 76T. All regions had high prevalence with the exception of Gambela in the southwest 7.6% (([95% CI 5.2-8.4%]) **(Figure S5B)**. Additional mutations in CRT are provided in **Table S3**.

240

249

241 Complexity of infection and parasite population structure

The majority of sequenced samples were monogenomic 745 (87.1%) (**Figure S6A**), consistent with previous reports^{5,35}, with some level variation in complexity of infection at the regional level (**Figure 4A**). The maximum COI detected was 4 (from Gambella Region) likely reflecting relatively low transmission in the study areas. Principal components (PC) 1 and 2 revealed distinct clustering of parasites from Gambella, supporting regional differentiation of the *P. falciparum* population within Ethiopia, but not by K13 622I status (**Figure 4B, Figure S7**).



250

Figure 4. Complexity of infection and population structure of *P. falciparum* in Ethiopia.
A) Complexity of infections for *P. falciparum* at a regional level. Colors indicate regions

and black dots inside violin plots indicate median COI. B) PCA plot of *P. falciparum* population at regional level. Colors indicate geography of sample origins and shapes
 indicate mutation K13 R622I status. Each diamond or dot indicates individual parasites.
 Percentage of variance explained by each PCA presented in each plot.

257

258 Spatial patterns of parasite relatedness and connectivity

We conducted IBD analysis of monogenomic infections to further elucidate the 259 connectivity of the parasite population across different regions. Overall, we observed a 260 261 tailed distribution of highly related parasite pairs (Figure 5A) with some level of spatial heterogeneity of proportion of pairs IBD for parasite population at each health center 262 (Figure 5B). The lowest average IBD sharing observed at Abol health center, Gambella 263 Region. We then conducted relatedness networks analysis to assess where haplotypes 264 265 sharing IBD above the specified threshold cluster geographic region or sample origin and found clear clustering of highly related parasite pairs (IBD≥0.90) within health 266 267 centers suggesting inbreeding and clonal transmission at local scale (Figure 5C). 268 However, occasional sharing of nearly clonal parasites was seen between clinics, suggesting long range parasite sharing. To identify if transmission of highly related 269 270 parasite pairs (IBD ≥ 0.90) were occurring between clinics in a within a region and 271 between different regions, we visualized a relatedness network on top of the Ethiopia 272 map and found that majority of the highly related pairs were distributed within regions or 273 nearby regions than distant regions. Connections between Gambella and other regions 274 were rare (Figure 5D). 275

- 276
- 077
- 277
- 278
- 279
- 280
- 281
- 282
- 283 284

It is made available under a CC-BY-NC-ND 4.0 International license .



286

285

Figure 5. *P. falciparum* parasite relatedness and connectivity across Ethiopia. A) 287 Pairwise IBD sharing across 12 health facilities. The plot shows the probability that any 288 two isolates are identical by descent, where the x axis indicates IBD values and the y289 axis indicates the frequency (%) of isolates sharing IBD. The inset highlights highly 290 291 related parasite pairs with a heavy tail in the distribution and some highly related pairs of samples having IBD≥0.90. B) Pairwise IBD sharing within a health facility. Boxes 292 293 indicate the interguartile range, the line indicates the median, the whiskers show the 95% confidence intervals and dots show outlier values. C) Relatedness network of 294 highly related parasite pairs (IBD≥0.90) at study site. Each dot indicates a sample and 295 colors correspond to health facilities across five regions in Ethiopia. Each node 296 identifies a unique isolate and an edge is drawn between two isolates if they share their 297 genome above IBD≥0.90. Isolates that do not share IBD≥0.90 of their genomes with 298

any other isolates are not shown. **D)** Spatial distribution of highly related parasite pairs

300 with IBD≥0.90. Color of circles or connecting lines represents the level of IBD sharing

within and between sites, respectively. The within site shading is based upon the mostrelated pair of parasites at the site.

303 Discussion

304 Findings from our genomic analysis of parasites collected across sentinel sites predominantly in 2022 suggest a critical threat of ArtR to ACT effectiveness in Ethiopia. 305 We identified increased prevalence and evidence of spread of the previously identified 306 307 WHO-validated ArtR K13 622I, with marked increases compared to previous reports. Here we see a prevalence of 622I up to 53.7% in Andansa Health Centre within the 308 Amhara region, as compared to 10% in 2018⁵ and 2.4% in 2014³⁴. Parasites carrying 309 622I are more closely related and clustered at health facility/district level compared to 310 311 wildtype parasites.

312 These findings are consistent with our previous report of clonal transmission in three regions of Ethiopia⁵. The highly-related, clonal nature of K13 622I mutant parasites 313 compared to wildtype parasites in this study is consistent with inbreeding and increasing 314 frequency within populations, especially in low transmission areas^{36,37}. Our findings 315 highlight the value of establishing genomic surveillance at malaria sentinel sites, 316 317 particularly how it can play a crucial role in tracking the emergence and spread of drug-318 resistant strains by providing continuous and localized monitoring of malaria parasite 319 populations. It also provides deeper insight into the genetic population structure of parasites circulating at these sites. Researchers in collaboration with the malaria control 320 program can detect early signals of resistance development, understand its 321 geographical spread, and assess the effectiveness of current treatments^{38,39}. 322

323 In addition to K13 622I, three WHO-validated K13 mutations (A675V from Gambella 324 Region; P441L from South and Oromia Regions, and P574L from Oromia Region) are reported for the first time in Ethiopia. These K13 mutations are becoming more common 325 in East Africa^{18,40-42}. The K13 441L mutation found in three health centers from different 326 327 geographic areas with variable malaria transmission and a recent increase in malaria 328 cases. The validated K13 P574L mutation was present in 5 samples from only one site, Batu health center in the Oromia region. K13 P574L mutations have each been shown 329 to have multiple independent origins throughout SE Asia⁴³ and have been reported in 330 Africa⁴⁴. 331

The K13 675V mutation was only found in one health center from Gambella Region of western Ethiopia neighboring South Sudan. This mutation was reported in isolates collected in Uganda beginning in 2016. It has proven to enhance parasite survival *in*

It is made available under a CC-BY-NC-ND 4.0 International license .

vitro and has been associated with resistance in vitro^{42,45}. Importation of the 675V 335 mutation seems probable given the IBD analysis showed lower relatedness and 4/6 of 336 337 the participants with the mutation reported travel. However, we cannot confirm whether the haplotype carrying this mutation are imported or locally emerged due lack of publicly 338 339 available WGS data with K13 675V mutations from East Africa. Potentially supporting the impact of travel and importation on parasites in Ethiopia, the parasite population 340 from Gambella did not cluster with other parasite populations in the country. This 341 differentiation could be for multiple reasons, such as different travel patterns in the 342 country, potentially supported by the low number of long-distance connections with 343 344 other clinics (Figure 5D). However, Gambella also shares a border with South Sudan 345 and receives a large number of refugees from across the border. Recent studies of South Sudanese refugees entering and arriving at the Ugandan Adjumani refugee camp 346 show 15.4% prevalence of $675V^{46}$. Combined, this suggests that 675V may be 347 spreading rapidly across South Sudan thereby entering Ethiopia. 348

- 349 Different studies propose that high efficacy of partner drugs, high prevalence of 350 polygenomic infections, and high parasite genetic diversity impede the spread of ACT resistance in Africa^{21,47},¹⁶. However, in this study we found a high prevalence of 351 mutations associated with lumefantrine resistance⁴⁸. The majority of genotyped samples 352 carried the MDR1 NFD haplotype^{49,50}, but three parasites with WHO-validated ArtR 353 markers in our study carry MDR1 NFD haplotypes that could lead to ACT failure. 354 Recent study showed that there is increasing prevalence of MDR1 NFD haplotypes in 355 recent vears in East Africa⁵¹. Moreover, the rollout of ACTs has led to an increase in the 356 MDR1 NFD haplotypes across several African studies, suggesting parasite populations 357 in Africa are under significant ACT selective pressure⁴⁹. With reports of decreased ACT 358 efficacy and treatment failure in Africa^{52–54}, the presence of partner drug mutations and 359 high prevalence of monogenomic infections suggests the conditions are ripe for ACT 360 361 failure in Ethiopia. Thus, close monitoring of ACT efficacy and preparation for deployment of alternative treatment strategies (e.g. multiple sequential therapies, 362 sequential ACT or triple ACT) are needed. 363
- This study does have limitations. First it does not address whether the mutations are 364 directly emerging locally or are imported. This will be possible as more genomic 365 information is produced from other areas of Africa and whole genome sequencing of 366 these isolates is done allowing for accurate tracking of K13 haplotypes. Second, it did 367 368 not address the impact of these mutations on clinical resistance as the in vitro efficacy 369 was not evaluated. Third, 12 sentinel sites do not represent the entirety of malaria epidemiology or parasite populations circulating in Ethiopia. Nonetheless, sampling 370 371 across most regions of the country provides valuable, generalizable information for the 372 malaria control program. Despite these limitations, these data provide important findings about how ArtR is spreading in the Horn of Africa which is critical information for malaria 373

It is made available under a CC-BY-NC-ND 4.0 International license .

control programs. Lastly, our data suggests importation and population movement may
play a role in the genetic patterns seen, but we do not have details on locations and
duration of travel to test this.

377 In conclusion, this study highlights critical challenges for malaria control including: 1) the 378 continued emergence and spread of the validated 622I mutation, 2) the detection of new 379 validated ArtR mutations in the Horn of Africa, and 3) the high rate of the co-occurrence 380 of ArtR with the MDR1 NFD haplotype associated with reduced sensitivity to 381 lumefantrine, the key partner drug in the region. It also raises additional questions about 382 the impact of importation and travel on the spread of antimalarial resistance, questions that will be answered as more genomic data from Africa becomes available. We also 383 384 demonstrate that sentinel surveillance systems can leverage genomics to provide critical information to control programs and potentially can help target where in vivo 385 386 studies should be focused to determine the clinical impacts of antimalarial resistance polymorphisms, as was done for validated ArtR in Tanzania due to the 561H 387 mutation^{11,41}. All of East Africa and the Horn of Africa are going to face significant 388 389 challenges in the years to come due to emerging antimalarial resistance, and malaria molecular surveillance will play a key role in fighting this emerging threat^{4,6,55}. 390

391

392 Methods

393 Study sites and sample collection

EPHI maintains 25 malaria sentinel sites, representing the variable eco-epidemiological 394 zones across the country. A series of cross-sectional studies were conducted in 12 of 395 396 these sites between 2019 and 2022 to assess the emergence and prevalence of 397 antimalarial drug resistance markers. The study sentinel sites included at least one area where large scale industry and irrigation, typically for sugar, is occurring and one 398 399 location in a border area (Figure 1A). From September to November of each year, 400 patients attending the outpatient department with signs and symptoms of malaria were 401 screened by microscopy. Microscopy occurred in the field and was reviewed by a 402 second expert microscopist at EPHI. In cases of discordance, a third reader was used, 403 blinded to previous reads. Inclusion criteria included P. falciparum positive by 404 microscopy. Patients less than 1 year or with severe malaria were excluded. Following 405 consent, a brief questionnaire was performed (including patient age, sex, malaria sign 406 and symptoms, travel history and demography), and dried blood spot (DBS) samples 407 were blotted onto Whatman 3 filter paper, air-dried, placed individually in a plastic bag 408 containing silica gel desiccant. These were stored at room temperature prior to transport to EPHI, and stored at -20 °C until used. 409

It is made available under a CC-BY-NC-ND 4.0 International license .

410

411 DNA extraction and MIP sequencing

412

413 DNA was extracted from DBS (one full DBS spot, typically involving 2 or 3 6mm 414 punches) using Chelex-Tween as previously described⁵⁶.

415

416 Five microliters of extracted DNA were used for each of the MIP captures using two 417 panels: one covering key *P. falciparum* drug resistance genes and mutations, including k13, mdr1, crt, dhfr, and dhps genes, and a newly designed panel of 305 MIPs targeting 418 common SNPs (>5%) SNPs (Table S4) (Niare et al. in preparation). MIP capture and 419 library preparation were performed as previously described^{5,57}. Sequencing was 420 conducted using an Illumina NextSeq 550 instrument (150 bp paired-end reads) at 421 422 Brown University (RI, USA). For samples with newly detected K13 441L, 574L and 675V, mutations in Ethiopia), an additional MIP capture was done using the same MIP 423 424 panel and resequenced to a high depth to confirm the mutations. Controls for each MIP capture and sequencing included genomic DNA from serial dilution of lab strain 3D7 as 425 426 well as no template and no probe controls.

427

428 Variant calling and filtering

The sequencing reads generated for each MIP panel were demultiplexed separately 429 using MIPtools software (https://github.com/bailey-lab/MIPTools) and further processed 430 using MIP Wrangler software (https://github.com/bailey-lab/MIPWrangler), in which 431 432 sequence reads sharing the same Unique Molecular Identifiers (UMIs) were collapsed 433 to generate a single consensus. Each dataset was analyzed by mapping sequence 434 reads to the P. falciparum 3D7 reference genome using Burrows-Wheeler Aligner (BWA)⁵⁸. Then variant calling was performed using freebayes software⁵⁹. To reduce 435 false positives due to PCR and alignment errors, the alternative allele needed to be 436 supported by more than one UMI within a sample, and the allele must have been 437 represented by at least 10 UMIs across the entire population. For genome wide SNPs, 438 only biallelic variant SNP positions were retained for downstream analysis. Low quality 439 SNPs (mapping quality < 30), were removed from the analysis using vcftools⁶⁰; 440 additionally, individual variant calls within each sample were set to missing if the site 441 442 was not supported by at least five UMIs. After these steps, SNPs with more than 50% missing data across samples, and subsequently samples with more than 50% of SNPs 443 missing, were removed from all downstream analyses⁵. 444

It is made available under a CC-BY-NC-ND 4.0 International license .

445 **Drug resistance prevalence estimation**

446 For drug resistance analysis, variants were annotated using the Pf 3D7 v3 reference 447 genome and gene features. Variants with a unique UMI count of 3 or greater used to 448 estimate prevalence key and known drug resistance mutations associated with different miplicorn 449 antimalarial resistance using the package R 4.2.1 software 450 (https://github.com/bailey-lab/miplicorn) and custom R script. With the exception of the 451 DHPS 437 mutation (which is mutant in the reference genome), drug resistance prevalence was determined considering both heterozygous or homozygous variants as 452 mutant alleles, while homozygous reference alleles considered as wild-type, and 453 missing loci not included for prevalence calculation (p=x/n*100), where p = prevalence, 454 x = number of mutant alleles, n = number of successfully genotyped loci. n is different 455 456 for each locus as each locus had independent success rates for genotyping. Prevalence and frequency bar plots were generated using the gaplot2 package and spatial 457 458 visualization of prevalence on maps of study areas were created using the sf package in R 4.2.1 software. Analysis of haplotypes included only samples where complete 459 460 genotypes across all involved variant sites were available and was plotted and 461 visualized using the UpSet package in R 4.2.1 software. Finally, the prevalence of each drug resistance marker was calculated at the health facility level. 462

463 Analysis of complexity of infectious and parasite population structure

The complexity of infection (COI) is the number of distinct parasite clones infecting a 464 single host. To estimate the number of clones per sample, the VCF file containing SNP 465 466 data was converted to THE REAL McCOIL categorical method format: heterozygous 467 call as 0.5, homozygous reference allele as 0, homozygous alternative allele as 1 and 468 no call as -1 and used as an input file for analysis of COI using THE REAL McCOIL R 469 package. To assess whether parasite populations within Ethiopia clustered per their 470 geographic origin, or by mutation status, we conducted principal component analysis 471 (PCA) using SNPRelate function in R 4.2.1 software and the result was visualized 472 ggplot2.

473 Analysis of parasite relatedness using Identity-by-descent (IBD)

We used identity-by-descent (IBD) to measure relatedness between parasites and identify regions of the genome shared with recent common ancestry using the *inbreeding_mle* function in MIPAnalyser software (v.1.0.1) (<u>https://github.com/mrc-</u> <u>ide/MIPanalyzer</u>) in R 4.2.1 software as previously described ⁶¹. In brief, both monogenomic and polygenomic infections (major alleles used for heterozygous positions) were included in the IBD analysis. Inbreeding_mle uses a Markov chain Monte Carlo to detect genomic regions that are identical by descent (IBD) and aids

It is made available under a CC-BY-NC-ND 4.0 International license .

simultaneous detection of parasite population clustering. Networks of highly-related
parasites per k13 mutation status or geographic origin (health facilities) created using
the *igraph* package in R 4.2.1 software. We then assessed IBD sharing at the regional
and local (health facility level) scales in order to assess spatial distribution of the
parasite population.

486

487 Data availability

488 All data produced in the present study are available upon reasonable request to the 489 authors.

490

Funding: This work was funded by the World Bank through the Africa CDC, with partial
support from the National Institute for Allergy and Infectious Diseases (R01AI177791 to
JBP, K24AI134990 to JJJ, and R01AI139520 to JAB).

- 494
- 495 Ethics

496 Before the commencement of the study, scientific and ethical approval was obtained 497 from the Ethiopian Public Health Institute's Institutional Review Board (EPHI-IRB), 498 protocol number EPHI-IRB-398-2021. In addition, respective permission and supporting 499 letters were obtained from the health facilities administration. All the necessary 500 precautionary and ethical methods were considered during the implementation of the 501 study for the patients and investigators. All screening forms and case record forms are 502 kept in a secured location, with access limited to authorized staff members. Unique 503 numerical identifiers were used for the computer-based data entry and blood samples. 504 Genotyping work conducted at Brown University was considered non-human subjects 505 research. Only aggregated clinical data and de-identified samples used for reporting individual level genotypes for publication. 506

507 Author contributions

508 BGB, AA, AAF, JBP, JJJ and JAB conceived the study. BGB led patient recruitment and 509 sample collection with contributions from HN, MK, HH, YW, GT, AA, MH, HS, AG, GA, 510 HS, GT and AA. BGB, AL and AAF performed laboratory work. BGB and AAF led 511 genetic data analysis and wrote the first draft of the manuscript. AA, JBP, JJJ and JAB 512 supported genetic data analysis and interpretations of results. All authors contributed to 513 the writing of the manuscript and approved the final version before submission.

514 Acknowledgments

515 The authors used an artificial intelligence language model for English language editing

516 during the writing process. However, the manuscript is original to the authors, who take

517 responsibility for its content.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 518
- 519

520 **Competing interests:** JBP reports research support from Gilead Sciences, non-521 financial support from Abbott Laboratories, and consulting for Zymeron Corporation, all 522 outside the scope of the current manuscript.

523 References

- World Health Organization. *World Malaria Report 2023.* (World Health Organization, 2023).
- 526 2. Bhatt, S. *et al.* The effect of malaria control on *Plasmodium falciparum* in Africa 527 between 2000 and 2015. *Nature* **526**, 207–211 (2015).
- 528 3. Beeson, J. G. *et al.* The RTS,S malaria vaccine: Current impact and foundation for 529 the future. *Sci. Transl. Med.* **14**, eabo6646 (2022).
- 4. Rosenthal, P. J. *et al.* The emergence of artemisinin partial resistance in Africa:
 how do we respond? *Lancet Infect. Dis.* (2024) doi:10.1016/S1473-3099(24)001415.
- 533 5. Fola, A. A. *et al. Plasmodium falciparum* resistant to artemisinin and diagnostics 534 have emerged in Ethiopia. *Nat Microbiol* **8**, 1911–1919 (2023).
- 535 6. Ishengoma, D. S. *et al.* Urgent action is needed to confront artemisinin partial
 536 resistance in African malaria parasites. *Nat. Med.* (2024) doi:10.1038/d41591-024537 00028-y.
- 538 7. Feleke, S. M. *et al. Plasmodium falciparum* is evolving to escape malaria rapid diagnostic tests in Ethiopia. *Nat Microbiol* **6**, 1289–1299 (2021).
- 540 8. Zinszer, K. & Talisuna, A. O. Fighting insecticide resistance in malaria control.
 541 *Lancet Infect. Dis.* 23, 138–139 (2023).
- 542 9. Emiru, T. *et al.* Evidence for a role of *Anopheles stephensi* in the spread of drug-543 and diagnosis-resistant malaria in Africa. *Nat. Med.* **29**, 3203–3211 (2023).
- 544 10. Nkumama, I. N., O'Meara, W. P. & Osier, F. H. A. Changes in Malaria
 545 Epidemiology in Africa and New Challenges for Elimination. *Trends Parasitol.* 33,
 546 128–140 (2017).
- Ishengoma, D. S. *et al.* Evidence of artemisinin partial resistance in northwestern
 Tanzania: clinical and molecular markers of resistance. *Lancet Infect. Dis.* (2024)
 doi:10.1016/S1473-3099(24)00362-1.
- Tumwebaze, P. *et al.* Changing Antimalarial Drug Resistance Patterns Identified by
 Surveillance at Three Sites in Uganda. *J. Infect. Dis.* 215, 631–635 (2017).
- 13. Dondorp, A. M. *et al.* Artemisinin resistance in *Plasmodium falciparum* malaria. *N. Engl. J. Med.* 361, 455–467 (2009).
- 14. Noedl Harald *et al.* Evidence of Artemisinin-Resistant Malaria in Western
 Cambodia. *N. Engl. J. Med.* **359**, 2619–2620.
- Tun, K. M. *et al.* Spread of artemisinin-resistant *Plasmodium falciparum* in
 Myanmar: a cross-sectional survey of the K13 molecular marker. *Lancet Infect. Dis.* **15**, 415–421 (2015).
- Ashley Elizabeth A. *et al.* Spread of Artemisinin Resistance in *Plasmodium falciparum Malaria. N. Engl. J. Med.* **371**, 411–423.

- 561 17. Uwimana, A. *et al.* Author Correction: Emergence and clonal expansion of in vitro
 562 artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in
 563 Rwanda. *Nat. Med.* 27, 1113–1115 (2021).
- Sea 18. Young, N. W. *et al.* High frequency of artemisinin partial resistance mutations in the
 great lake region revealed through rapid pooled deep sequencing. *medRxiv* (2024)
 doi:10.1101/2024.04.29.24306442.
- Juliano, J. J. *et al.* Prevalence of mutations associated with artemisinin partial
 resistance and sulfadoxine-pyrimethamine resistance in 13 regions in Tanzania in
 2021: a cross-sectional survey. *Lancet Microbe* 100920 (2024).
- Mihreteab, S. *et al.* Increasing Prevalence of Artemisinin-Resistant HRP2-Negative
 Malaria in Eritrea. *N. Engl. J. Med.* 389, 1191–1202 (2023).
- 572 21. Balikagala, B. *et al.* Evidence of Artemisinin-Resistant Malaria in Africa. *N. Engl. J.* 573 *Med.* 385, 1163–1171 (2021).
- van Loon, W. *et al.* Detection of Artemisinin Resistance Marker Kelch-13 469Y in *Plasmodium falciparum,* South Kivu, Democratic Republic of the Congo, 2022. Am. *J. Trop. Med. Hyg.* **110**, 653–655 (2024).
- 577 23. Dhorda, M. *et al.* Artemisinin-resistant malaria in Africa demands urgent action.
 578 *Science* 385, 252–254 (2024).
- 579 24. Rosado, J. *et al. Ex vivo* susceptibility to antimalarial drugs and polymorphisms in 580 drug resistance genes of African *Plasmodium falciparum*, 2016-2023: a genotype-581 phenotype association study. *bioRxiv* (2024) doi:10.1101/2024.07.17.24310448.
- 582 25. Hamlet, A. *et al.* The potential impact of *Anopheles stephensi* establishment on the
 583 transmission of *Plasmodium falciparum* in Ethiopia and prospective control
 584 measures. *BMC Med.* 20, 135 (2022).
- 585 26. Messenger, L. A. *et al.* Insecticide resistance in *Anopheles arabiensis* from Ethiopia
 586 (2012-2016): a nationwide study for insecticide resistance monitoring. *Malar. J.* 16,
 587 469 (2017).
- Nigussie, T. Z., Zewotir, T. & Muluneh, E. K. Effects of climate variability and
 environmental factors on the spatiotemporal distribution of malaria incidence in the
 Amhara national regional state, Ethiopia. Spat. Spatiotemporal Epidemiol. 40,
 100475 (2022).
- 592 28. Tandoh, K. Z., Duah-Quashie, N. O., Raman, J. & Ochola-Oyier, L. I. Editorial:
 593 Malaria molecular epidemiology current situation in Africa. *Front Epidemiol* 4,
 594 1400612 (2024).
- Inzaule, S. C., Tessema, S. K., Kebede, Y., Ogwell Ouma, A. E. & Nkengasong, J.
 N. Genomic-informed pathogen surveillance in Africa: opportunities and challenges. *Lancet Infect. Dis.* 21, e281–e289 (2021).
- Schaffner, S. F. *et al.* Malaria surveillance reveals parasite relatedness, signatures
 of selection, and correlates of transmission across Senegal. *Nat. Commun.* 14,
 7268 (2023).
- Fola, A. A. *et al.* Genomics reveals heterogeneous *Plasmodium falciparum* transmission and selection signals in Zambia. *Commun. Med.* 4, 67 (2024).
- 603 32. Struelens, M. J. *et al.* Real-time genomic surveillance for enhanced control of 604 infectious diseases and antimicrobial resistance. *Front. Sci. Ser.* **2**, (2024).
- 33. Golumbeanu, M., Edi, C. A. V., Hetzel, M. W., Koepfli, C. & Nsanzabana, C.
- Bridging the Gap from Molecular Surveillance to Programmatic Decisions for

It is made available under a CC-BY-NC-ND 4.0 International license .

607 Malaria Control and Elimination. Am. J. Trop. Med. Hyg. (2023) 608 doi:10.4269/ajtmh.22-0749. 609 34. Bayih, A. G. et al. A Unique Plasmodium falciparum K13 Gene Mutation in 610 Northwest Ethiopia. Am. J. Trop. Med. Hyg. 94, 132–135 (2016). 611 35. Abera, D. et al. Genomic analysis reveals independent evolution of Plasmodium 612 falciparum populations in Ethiopia. Malar. J. 20, 129 (2021). 613 36. Anderson, T. J. et al. Microsatellite markers reveal a spectrum of population 614 structures in the malaria parasite Plasmodium falciparum. Mol. Biol. Evol. 17, 615 1467-1482 (2000). 616 37. Camponovo, F., Buckee, C. O. & Taylor, A. R. Measurably recombining malaria 617 parasites. Trends Parasitol. 39, 17-25 (2023). 38. Neafsey, D. E. & Volkman, S. K. Malaria Genomics in the Era of Eradication. Cold 618 619 Spring Harb. Perspect. Med. 7, (2017). 620 39. Auburn, S. & Barry, A. E. Dissecting malaria biology and epidemiology using 621 population genetics and genomics. Int. J. Parasitol. 47, 77–85 (2017). 622 40. Meier-Scherling, C. P. G. et al. Selection of artemisinin partial resistance Kelch13 623 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously 624 in South-East Asia. medRxiv (2024) doi:10.1101/2024.02.03.24302209. 625 41. Juliano, J. J. et al. Country wide surveillance reveals prevalent artemisinin partial 626 resistance mutations with evidence for multiple origins and expansion of high level 627 sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. *medRxiv* 628 (2023) doi:10.1101/2023.11.07.23298207. 629 42. Conrad, M. D. et al. Evolution of Partial Resistance to Artemisinins in Malaria 630 Parasites in Uganda. N. Engl. J. Med. 389, 722-732 (2023). 631 43. Stokes, B. H. et al. Plasmodium falciparum K13 mutations in Africa and Asia impact 632 artemisinin resistance and parasite fitness. Elife 10, (2021). 44. Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant 633 634 Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 635 1602–1608 (2020). 45. Ikeda, M. et al. Artemisinin-Resistant Plasmodium falciparum with High Survival 636 637 Rates, Uganda, 2014-2016. Emerg. Infect. Dis. 24, 718–726 (2018). 638 46. Tukwasibwe, S. et al. Varied Prevalence of Antimalarial Drug Resistance Markers 639 in Different Populations of Newly Arrived Refugees in Uganda. J. Infect. Dis. 230, 497-504 (2024). 640 641 47. Talisuna, A. O. et al. Mitigating the threat of artemisinin resistance in Africa: 642 improvement of drug-resistance surveillance and response systems. Lancet Infect. 643 Dis. 12, 888–896 (2012). 644 48. Grais, R. F. et al. Molecular markers of resistance to amodiaguine plus 645 sulfadoxine-pyrimethamine in an area with seasonal malaria chemoprevention in south central Niger. Malar. J. 17, 1-9 (2018). 646 49. Okell, L. C. et al. Emerging implications of policies on malaria treatment: genetic 647 changes in the Pfmdr-1 gene affecting susceptibility to artemether-lumefantrine and 648 649 artesunate-amodiaguine in Africa. BMJ Glob Health 3, e000999 (2018). 650 50. Veiga, M. I. et al. Globally prevalent PfMDR1 mutations modulate Plasmodium 651 falciparum susceptibility to artemisinin-based combination therapies. Nat. Commun. **7**, 11553 (2016). 652

It is made available under a CC-BY-NC-ND 4.0 International license .

51. Fola, A. A. *et al.* Temporal genomic analysis of *Plasmodium falciparum* reveals
increased prevalence of mutations associated with delayed clearance following
treatment with artemisinin-lumefantrine in Choma District, Southern Province,
Zambia. *medRxiv* (2024) doi:10.1101/2024.06.05.24308497.

- 52. Ekland, E. H. & Fidock, D. A. Advances in understanding the genetic basis of antimalarial drug resistance. *Curr. Opin. Microbiol.* **10**, 363–370 (2007).
- 659 53. Guyant, P. *et al.* Past and new challenges for malaria control and elimination: the
 660 role of operational research for innovation in designing interventions. *Malar. J.* 14,
 661 279 (2015).
- 54. Arya, A., Kojom Foko, L. P., Chaudhry, S., Sharma, A. & Singh, V. Artemisininbased combination therapy (ACT) and drug resistance molecular markers: A
 systematic review of clinical studies from two malaria endemic regions India and
 sub-Saharan Africa. International Journal for Parasitology: Drugs and Drug
 Resistance vol. 15 43–56 Preprint at https://doi.org/10.1016/j.ijpddr.2020.11.006
 (2021).
- 668 55. Assefa, A., Fola, A. A. & Tasew, G. Emergence of *Plasmodium falciparum* strains
 669 with artemisinin partial resistance in East Africa and the Horn of Africa: is there a
 670 need to panic? *Malar. J.* 23, 34 (2024).
- 56. Teyssier, N. B. *et al.* Optimization of whole-genome sequencing of *Plasmodium falciparum* from low-density dried blood spot samples. *Malar. J.* **20**, 116 (2021).
- 673 57. Verity, R. et al. The impact of antimalarial resistance on the genetic structure of 674 *Plasmodium falciparum* in the DRC. *Nat. Commun.* 11, 2107 (2020).
- 58. Li, H. Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM. (2014) doi:10.6084/M9.FIGSHARE.963153.V1.
- 59. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. *arXiv* [*q-bio.GN*] (2012).
- 679 60. Danecek, P. *et al.* The variant call format and VCFtools. *Bioinformatics* **27**, 2156– 680 2158 (2011).
- 681 61. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of 682 *Plasmodium falciparum* in the DRC. *Nat. Commun.* **11**, 2107 (2020).
- 683
- 684
- 685
- 686
- 687
- 688
- 689
- 690
- 691

It is made available under a CC-BY-NC-ND 4.0 International license .

- 692
 693
 694
 695 Supplementary materials
 696
 697 Supplementary Figures
- 698
- 699



Samples

- 701
- Figure S1. MIP sequencing coverage for genome-wide SNPs. Heatmap color shows samples ($n \equiv 0.855$, columns) and loci ($n \equiv 0.1415$, rows) coverage retained after
- filtering for downstream analysis. 112 1413, 1003 toverage relation for downstream analysis.
- 704 Intel 705
- 706

It is made available under a CC-BY-NC-ND 4.0 International license .



707

708 Figure S2. WHO validated K13 mutations prevalence at health facility level. Bar

709 **plots show** prevalence of the indicated mutations at health facility level per region.

710 Colours indicate mutations

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S3. Prevalence of non-synonymous mutations across the *K13* gene, coloured

according to amino-acid residues within beta propeller domain where validated

716 resistance mutations are located or not.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S4. Comparison of relatedness of mutant vs wildtype. A) Plot shows the
mean IBD within K13 P441L mutant versus wildtype parasites. B) Plot shows the mean
IBD within K13 P574L mutant versus wild type parasites. C) Plot shows the mean IBD
within K13 A675V mutant versus wild type parasites. Color codes correspond to *kelch13*R622I mutant and wild parasites.

742 Fig S5. Prevalence of SP (A) and CRT K76T (B) mutations in Ethiopia. A)

commutative prevalence of different SP markers. Bars indicate individual mutation and
 colors indicate gene. B) Prevalence of CRT K76T prevalence at health facility level.

746

747

It is made available under a CC-BY-NC-ND 4.0 International license .

750 **Figure S6. Complexity of infections across sequenced samples.**

751

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S7. Population structure of *P. falciparum* populations per 622l mutation
 and Health facility level across five regions in Ethiopia. Colors indicate geographic
 sample origins and shapes indicate mutation status. Each diamond or dot indicates
 individual parasites. Percentage of variance explained by each PCA presented in each
 plot.

- 769 Supplementary tables

It is made available under a CC-BY-NC-ND 4.0 International license .

To assess and view easily all supplementary tables compiled in one excel sheet.

772

Table S1. Details of samples sequenced per region, health facility and year of samplecollection.

775

Table S2. Metadata and genotype file for all successfully sequenced samples for drug
resistance loci. Only successfully sequenced samples were used for drug resistance
marker prevalence estimates. 0=Reference call (Wildtype), 1=Alternative heterozygous
call (Mixed mutant), 2=Alternative homozygous call (Pure mutant), -1=Missing call. Note
that the number of samples successfully genotyped varies per locus drug resistance
MIP panel.

- 782
- **Table S3.** Prevalence of key mutation per health facility, n=number samples sequenced
 at each health center and % prevalence of key mutation.
- 785

Table S4. List of molecular inversion probes (IBC2CORE MIPs) designed targetinggenome-wide geographic informative SNPs.